MDxHealth shares surge 10.48% after-hours as analysts forecast breakeven by 2027.

MDxHealth surged 10.48% in after-hours trading following analyst forecasts suggesting the company could turn a profit of $2.3 million in 2027, with expectations of an 81% compound annual growth rate to reach breakeven by 2027. The report highlighted improved financial metrics, including a reduced loss trajectory, and underscored high confidence in the company’s growth potential despite its current negative equity. While the analysis emphasized biotech sector volatility and cash flow uncertainties, the projected path to profitability aligned with the stock’s upward movement, reflecting investor optimism about near-term turnaround prospects.